Preclinical Drug Development

SRI Biosciences provides clients with a wide range of services for moving new drug candidates from the laboratory into clinical testing and to the marketplace. The only full-service contract research organization based on the West Coast, SRI works with large and small pharmaceutical and biotechnology clients, including global pharmaceutical companies and start-up biotechnology ventures.

 

We also serve the nonclinical needs of the National Cancer Institute (NCI), the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Mental Health (NIMH), and the National Institute of Aging (NIA).

 

Scope of Services

To help clients meet their product development objectives, SRI Biosciences offers services ranging from comprehensive drug safety evaluations to scale-up processing of prototype clinical trial materials (CTMs).  We provide clients with more than 50 years of expertise and facilities equipped with sophisticated scientific instrumentation. We have AAALAC-accredited facilities and a modern functional manufacturing facility, including an aseptic processing suite.

All of SRI's pharmaceutical development services meet worldwide stringent regulatory requirements. SRI studies are conducted under Good Laboratory Practice (GLP) and current Good Manufacturing Practice (cGMP) regulations. For biotech and pharmaceutical clients that need specialized expertise in the discovery phase, SRI provides discovery services for target research initiatives or as an ongoing development resource.

Key development services include

Press Releases

Researchers Developing New Multiple Sclerosis Drug That Can Be Taken Orally

Researchers at SRI are developing a new Multiple Sclerosis drug that can be taken by mouth. It will be more convenient than current treatments, which require frequent hospital visits for injections or intravenous infusions.

Topics: Alternative Drug Delivery Systems Drug Formulation Development Drug Pipeline Immunology + Inflammation Medicinal Chemistry Pharmaceutical R+D Pharmaceutical Sciences: Stability Studies Preclinical Drug Development
researchers in SRI lab
SRI International Awarded Contract Worth Up to $100M from National Institute of Allergy and Infectious Diseases

SRI International has been awarded a contract worth up to $100.5 million over 10 years from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)

Topics: Disease Focus Areas Drug Discovery Immunology + Inflammation Infectious Diseases Metabolic Diseases Microbiology Pharmaceutical R+D Pre-formulation Studies Preclinical Drug Development Target Validation + Assay Development Vaccine Development
SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts

SRI International has been awarded two National Cancer Institute (NCI) preclinical service contracts totaling $14.3 million. The contracts provide SRI up to $11.7 million for toxicology studies and an additional $2.6 million for pharmacology and pharmacokinetics studies.

Topics: Basic Cancer Research Cancer Drug Discovery Pharmaceutical R+D Preclinical Drug Development Safety Pharmacology
microscopic view of the HIV virus
SRI International Researchers Developing Bioadhesive Gel to Protect Women from HIV and HSV Infections

Researchers are developing and testing a topical microbicide gel for drug delivery. The innovative formulation will be a combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.

Topics: Alternative Drug Delivery Systems Drug Formulation Development Drug Pipeline Infectious Diseases Pharmaceutical R+D Pharmaceutical Sciences: Analytical Chemistry Pharmaceutical Sciences: Stability Studies Preclinical Drug Development
DNA gyrase
SRI Researchers Validate Preclinical Effectiveness of Tuberculosis Drug Target that Could Shorten Treatment Time

In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time.

Topics: Disease Focus Areas Drug Discovery Infectious Diseases Microbiology Pharmaceutical R+D Preclinical Drug Development
SRI Shenandoah Valley to Expand Operations

SRI Shenandoah Valley has authorized the build-out of the remaining space in its 40,000 square foot state-of-the-art research facility in the Rockingham Center for Research and Technology.

Topics: Infectious Diseases Pharmaceutical R+D Preclinical Drug Development Proteomics Vaccine Development

Events

pills
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting

SRI Biosciences will exhibit.

Topics: Pharmaceutical R+D Preclinical Drug Development

Divisions, Centers + Labs